Evaluation of Low Source of Signal in SCOUT DS (LSS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
VeraLight, Inc.
ClinicalTrials.gov Identifier:
NCT01339637
First received: April 18, 2011
Last updated: December 3, 2012
Last verified: December 2012

April 18, 2011
December 3, 2012
April 2011
September 2011   (final data collection date for primary outcome measure)
Validation of the SCOUT DS algorithm comparing it to Oral Glucose Tolerance Test in dark skinned individuals [ Time Frame: 6 months ] [ Designated as safety issue: No ]
The primary study endpoint is the relative true positive and relative true negative fractions between the SCOUT DS and FPG test for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL).
Compare SCOUT DS and FPG to Oral Glucose Tolerance Test [ Time Frame: 6 months ] [ Designated as safety issue: No ]
The primary study endpoint is the relative true positive and relative true negative fractions between the SCOUT DS and FPG test for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL).
Complete list of historical versions of study NCT01339637 on ClinicalTrials.gov Archive Site
Compare SCOUT DS and FPG to HbA1c [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Secondary endpoint is to evaluate the receiver operator characteristic area under the curve, sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values of SCOUT DS, FPG, and A1C test for detection of abnormal glucose tolerance.
Same as current
Not Provided
Not Provided
 
Evaluation of Low Source of Signal in SCOUT DS
Evaluation of Low Source of Signal in SCOUT DS

The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score (DRS).

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Community sample

  • Metabolic Syndrome
  • Impaired Glucose Tolerance
  • Gestational Diabetes
Not Provided
Diabetes risk factors
Very dark skin subjects with with diabetes risk factors
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
196
October 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Dark Skin Tone (Von Luschan chromatic skin color > 35)
  2. Age greater than or equal to 45 years;

    OR

  3. Age 18 to 44 years and a BMI > 25 kg/m² with one or more of the following diabetes risk factors:

    • Habitually physically inactive (less than 30 minutes of moderate physical activity most, if not all, days of the week)
    • Has a first-degree relative with type 2 diabetes
    • African American, Latino, Native American, Asian American, Pacific Islander
    • Has delivered a baby weighing > 9 lb or previously diagnosed with gestational diabetes
    • Hypertension (≥140/≥ 90 mmHg) or being treated for hypertension
    • HDL cholesterol level < 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
    • Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
    • Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 years
    • Conditions associated with insulin resistance such as severe obesity or acanthosis nigricans
    • History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease

Exclusion Criteria:

  • Prior participation under VeraLight protocols: VL-2710, VL-2711 or VL-2712
  • Under 18 years of age
  • Receiving investigational treatments in the past 14 days
  • Psychosocial issues that interfere with an ability to follow study procedures
  • Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
  • Diagnosed with any type of diabetes, including type 1 or 2
  • Taking glucose lowering medications
  • Known to be pregnant
  • Receiving dialysis or having known renal compromise
  • Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
  • Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded
  • Current chemotherapy, or chemotherapy within the past 12 months
  • Receiving medications that fluoresce*
  • Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
  • Known to have, or at risk for, sensitivity to skin lotions or shaving (creams, lotions, soap, shaving cream)
  • Prior bariatric surgery
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01339637
VL-2718
No
VeraLight, Inc.
VeraLight, Inc.
Not Provided
Study Director: John Maynard, MS VeraLight, Inc.
VeraLight, Inc.
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP